



PB 108 of 2012

National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012 (No. 9)¹

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under sections 84AF, 84AK, 85, 85A, 88 and 101 of the *National Health Act 1953*.

Dated 11th December 2012

FELICITY McNEILL

First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing

1 Name of Instrument

(1) This Instrument is the *National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2012 (No. 9)*.

(2) This Instrument may also be cited as PB 108 of 2012.

2 Commencement

This Instrument commences on 1 January 2013.

3 Amendment of *National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)*

Schedule 1 amends the *National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)*.

Schedule 1 Amendments

[1] Schedule 1, entry for Betamethasone

omit:

Ointment 500 micrograms (as valerate) per g, 15 g	Application	Betnovate 1/2	QA	MP NP	C1422	1	1	1
		Cortival 1/2	FM	MP NP	C1422	1	1	1

[2] Schedule 1, entry for Bicalutamide

omit from the column headed "Responsible Person" for the brand "Cosudex": **SZ** substitute: **AP**

[3] Schedule 1, entry for Clopidogrel in the form Tablet 75 mg (as hydrogen sulfate)

omit from the column headed "Circumstances" for the brands "APO-Clopidogrel", Clopidogrel Winthrop", "Iscover" and "Plavix":

C3146 C3879

insert in numerical order:

C4165 C4166

[4] Schedule 1, entry for Clopidogrel in the form Tablet 75 mg (as besilate)

insert in numerical order in the column headed "Circumstances" for the brand "Clovix 75":

C4165 C4166

[5] Schedule 1, entry for Famciclovir in the form Tablet 500 mg [Max Quantity 56; Number of Repeats 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Famciclovir generichealth 500	GQ	MP NP	C3626 C3627 C3628 C3629	P3626 P3627 P3628 P3629	56	5	56
----------------------------------	----	-------	----------------------------	----------------------------	----	---	----

[6] Schedule 1, entry for Felodipine in each of the forms: Tablet 2.5 mg (extended release); Tablet 5 mg (extended release); and Tablet 10 mg (extended release)

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Fendex ER	AF	MP NP	30	5	30
-----------	----	-------	----	---	----

[7] Schedule 1, entry for Fentanyl in the form Transdermal patch 2.063 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Dutran 12	GM	MP NP	C1062	5	0	5
-----------	----	-------	-------	---	---	---

[8] Schedule 1, entry for Fentanyl in the form Transdermal patch 4.125 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Dutran 25	GM	MP NP	C1062	5	0	5
-----------	----	-------	-------	---	---	---

[9] Schedule 1, entry for Fentanyl in the form Transdermal patch 8.25 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Dutran 50	GM	MP NP	C1062	5	0	5
-----------	----	-------	-------	---	---	---

[10] Schedule 1, entry for Fentanyl in the form Transdermal patch 12.375 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Dutran 75	GM	MP NP	C1062	5	0	5
-----------	----	-------	-------	---	---	---

[11] Schedule 1, entry for Fentanyl in the form Transdermal patch 16.5 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Dutran 100	GM	MP NP	C1062	5	0	5
------------	----	-------	-------	---	---	---

[12] Schedule 1, entry for Fluoxetine in the form Capsule 20 mg (as hydrochloride)

omit from the column headed "Brand": **Auscap** *substitute:* **Auscap Aspen**

[13] Schedule 1, entry for Lamotrigine in the form Tablet 25 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Lamotrigine Aspen 25	AS	MP NP	C1426	56	5	56
-------------------------	----	-------	-------	----	---	----

[14] Schedule 1, entry for Lamotrigine in the form Tablet 100 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Lamotrigine Aspen 100	AS	MP NP	C1426	56	5	56
--------------------------	----	-------	-------	----	---	----

[15] Schedule 1, entry for Macrogol 3350 in the form Powder for oral solution 510 g

(a) *omit:*

your pharmacy Clear Laxative	OY	MP NP	C1263 C1613 C2693 C2823 C3642 C3643	P3643	2	0	1
---------------------------------	----	-------	---	-------	---	---	---

(b) omit:

your pharmacy Clear Laxative	OY	MP NP	C1263 C1613 C2693 C2823 C3642 C3643	P3642	2	3	1
---------------------------------	----	-------	---	-------	---	---	---

(c) omit:

your pharmacy Clear Laxative	OY	MP NP	C1263 C1613 C2693 C2823 C3642 C3643	P1263 P1613 P2693 P2823	1	5	1
---------------------------------	----	-------	---	----------------------------	---	---	---

- [16] Schedule 1, entry for Mirtazapine in each of the forms: Tablet 15 mg (orally disintegrating); Tablet 30 mg (orally disintegrating); and Tablet 45 mg (orally disintegrating)

omit from the column headed "Brand": Mirtazapine Pfizer substitute: Mirtazapine Dispersible Pfizer

- [17] Schedule 1, entry for Mycophenolic Acid in the form Capsule containing mycophenolate mofetil 250 mg

(a) omit:

Cellplant	WQ	MP	C1765 C1766		300	3	100
-----------	----	----	-------------	--	-----	---	-----

(b) omit:

Cellplant	WQ	MP See Note 1	C1650 C1651 C3355 C3356		600	5	100	C(100)
-----------	----	------------------	----------------------------	--	-----	---	-----	--------

- [18] Schedule 1, entry for Mycophenolic Acid in the form Capsule containing mycophenolate mofetil 500 mg

(a) omit:

Cellplant	WQ	MP	C1765 C1766		150	3	50
-----------	----	----	-------------	--	-----	---	----

(b) omit:

Cellplant	WQ	MP See Note 1	C1650 C1651 C3355 C3356		300	5	50	C(100)
-----------	----	------------------	----------------------------	--	-----	---	----	--------

- [19] Schedule 1, entry for Pantoprazole in the form Tablet (enteric coated) 40 mg (as sodium sesquihydrate) [Max Quantity 30; Number of Repeats 2]

(a) omit from the column headed "Responsible Person" for the brand "Panto": NZ substitute: TK

(b) omit from the column headed "Responsible Person" for the brand "Pantoloc": NH substitute: TE

- [20] Schedule 1, entry for Pantoprazole in the form Tablet (enteric coated) 40 mg (as sodium sesquihydrate) [Max Quantity 30; Number of Repeats 5]

(a) omit from the column headed "Responsible Person" for the brand "Panto": NZ substitute: TK

(b) omit from the column headed "Responsible Person" for the brand "Pantoloc": NH substitute: TE

[21] Schedule 1, entry for Pantoprazole in the form Tablet (enteric coated) 20 mg (as sodium sesquihydrate)

- (a) omit from the column headed "Responsible Person" for the brand "Panto": **NZ** substitute: **TK**
 (b) omit from the column headed "Responsible Person" for the brand "Pantoloc": **NH** substitute: **TE**

[22] Schedule 1, entry for Rabeprazole in the form Tablet containing rabeprazole sodium 10 mg (enteric coated)

- (a) omit from the column headed "Brand": **Parzole 10** substitute: **Parzol 10**
 (b) insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Razit 10	DO	MP NP	C1337 C1533	28	5	28
----------	----	-------	-------------	----	---	----

[23] Schedule 1, entry for Rabeprazole in the form Tablet containing rabeprazole sodium 20 mg (enteric coated) [Max Quantity 30; Number of Repeats 2]

- (a) omit from the column headed "Brand": **Parzole 20** substitute: **Parzol 20**
 (b) insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Razit 20	DO	MP NP	C1177 C1337 P1177 C1533	30	2	30
----------	----	-------	-------------------------	----	---	----

- (c) insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

STADA Rabeprazole	TD	MP NP	C1177 C1337 P1177 C1533	30	2	30
----------------------	----	-------	-------------------------	----	---	----

[24] Schedule 1, entry for Rabeprazole in the form Tablet containing rabeprazole sodium 20 mg (enteric coated) [Max Quantity 30; Number of Repeats 5]

- (a) omit from the column headed "Brand": **Parzole 20** substitute: **Parzol 20**
 (b) insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Razit 20	DO	MP NP	C1177 C1337 P1337 P1533 C1533	30	5	30
----------	----	-------	-------------------------------	----	---	----

- (c) insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

STADA Rabeprazole	TD	MP NP	C1177 C1337 P1337 P1533 C1533	30	5	30
----------------------	----	-------	-------------------------------	----	---	----

[25] Schedule 1, entry for Risperidone in the form Tablet 0.5 mg [Max Quantity 60; Number of Repeats 2]

- (a) omit:

Resdone 0.5	CR	MP NP	C1589 C2061 P2061 P3083 C3083	60	2	60
-------------	----	-------	-------------------------------	----	---	----

- (b) insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Rispericor 0.5	CR	MP NP	C1589 C2061 P2061 P3083 C3083	60	2	60
----------------	----	-------	-------------------------------	----	---	----

[26] Schedule 1, entry for Risperidone in the form Tablet 0.5 mg [Max Quantity 60; Number of Repeats 5]

(a) *omit:*

Resdone 0.5	CR	MP NP	C1589 C2061 C3083	P1589	60	5	60
-------------	----	-------	----------------------	-------	----	---	----

(b) *insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":*

Rispericor 0.5	CR	MP NP	C1589 C2061 C3083	P1589	60	5	60
----------------	----	-------	----------------------	-------	----	---	----

[27] Schedule 1, entry for Risperidone in the form Tablet 1 mg [Max Quantity 60; Number of Repeats 2]

(a) *omit:*

Resdone 1	CR	MP NP	C1589 C2061 C2272 C3083	P2061 P3083	60	2	60
-----------	----	-------	----------------------------	-------------	----	---	----

(b) *insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":*

Rispericor 1	CR	MP NP	C1589 C2061 C2272 C3083	P2061 P3083	60	2	60
--------------	----	-------	----------------------------	-------------	----	---	----

[28] Schedule 1, entry for Risperidone in the form Tablet 1 mg [Max Quantity 60; Number of Repeats 5]

(a) *omit:*

Resdone 1	CR	MP NP	C1589 C2061 C2272 C3083	P1589 P2272	60	5	60
-----------	----	-------	----------------------------	-------------	----	---	----

(b) *insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":*

Rispericor 1	CR	MP NP	C1589 C2061 C2272 C3083	P1589 P2272	60	5	60
--------------	----	-------	----------------------------	-------------	----	---	----

[29] Schedule 1, entry for Risperidone in the form Tablet 2 mg [Max Quantity 60; Number of Repeats 2]

(a) *omit:*

Resdone 2	CR	MP NP	C1589 C2272 C3083	P3083	60	2	60
-----------	----	-------	----------------------	-------	----	---	----

(b) *insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":*

Rispericor 2	CR	MP NP	C1589 C2272 C3083	P3083	60	2	60
--------------	----	-------	----------------------	-------	----	---	----

[30] Schedule 1, entry for Risperidone in the form Tablet 2 mg [Max Quantity 60; Number of Repeats 5]

(a) *omit:*

Resdone 2	CR	MP NP	C1589 C2272 C3083	P1589 P2272	60	5	60
-----------	----	-------	----------------------	-------------	----	---	----

(b) insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Rispericor 2	CR	MP NP	C1589 C2272 C3083	P1589 P2272	60	5	60
--------------	----	-------	----------------------	-------------	----	---	----

[31] Schedule 1, entry for Risperidone in the form Tablet 3 mg

(a) omit:

Resdone 3	CR	MP NP	C1589 C2272		60	5	60
-----------	----	-------	-------------	--	----	---	----

(b) insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Rispericor 3	CR	MP NP	C1589 C2272		60	5	60
--------------	----	-------	-------------	--	----	---	----

[32] Schedule 1, entry for Risperidone in the form Tablet 4 mg

(a) omit:

Resdone 4	CR	MP NP	C1589 C2272		60	5	60
-----------	----	-------	-------------	--	----	---	----

(b) insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":

Rispericor 4	CR	MP NP	C1589 C2272		60	5	60
--------------	----	-------	-------------	--	----	---	----

[33] Schedule 1, entry for Terbinafine in the form Tablet 250 mg (as hydrochloride)

(a) omit:

Terbix 250	MI	MP NP	C2191 C2865 C3244	P2865 P3244	42	0	42
------------	----	-------	----------------------	-------------	----	---	----

(b) omit:

Terbix 250	MI	MP NP	C2191 C2865 C3244	P2191	42	1	42
------------	----	-------	----------------------	-------	----	---	----

[34] Schedule 1, entry for Tramadol in the form Capsule containing tramadol hydrochloride 50 mg

(a) omit:

GenRx Tramadol	GX	MP NP	C1497 C1615	P1497	20	0	20
		PDP	C1497 C1615		20	0	20

(b) omit:

GenRx Tramadol	GX	MP NP	C1497 C1615	P1615	20	2	20
----------------	----	-------	-------------	-------	----	---	----

[35] Schedule 1, entry for Tramadol

(a) omit:

Tablet (extended release) containing tramadol hydrochloride 100 mg	Oral	Durotram XR	IA	MP NP	C1537	10	0	10
--	------	-------------	----	-------	-------	----	---	----

(b) omit:

Tablet (extended release) containing tramadol hydrochloride 200 mg	Oral	Durotram XR	IA	MP NP	C1537	10	0	10
--	------	-------------	----	-------	-------	----	---	----

(c) omit:

Tablet (extended release) containing tramadol hydrochloride 300 mg	Oral	Durotram XR	IA	MP NP	C1537	10	0	10
--	------	-------------	----	-------	-------	----	---	----

[36] **Schedule 1, entry for Venlafaxine in each of the forms: Capsule (modified release) 75 mg (as hydrochloride); and Capsule (modified release) 150 mg (as hydrochloride)**

omit from the column headed "Brand": **STADA Venlafaxine SR** substitute: **STADA Venlafaxine-SR**

[37] **Schedule 3**

omit:

NH	Nycomed Healthcare Pty Limited	55 140 659 374
----	--------------------------------	----------------

[38] **Schedule 3, details relevant to Responsible person code NQ**

omit: **Nycomed Pty Ltd** substitute: **Takeda Pharmaceuticals Australia Pty Ltd**

[39] **Schedule 3**

omit:

NZ	Nycomed Services Pty Limited	15 140 661 123
----	------------------------------	----------------

[40] **Schedule 3, after details relevant to Responsible person code TD**

insert:

TE	Takeda Pharmaceuticals Australia Pty Ltd	71 095 610 870
TK	Takeda Pharmaceuticals Australia Pty Ltd	71 095 610 870

[41] **Schedule 4, Part 1, entry for Clopidogrel**

(a) omit:

	C3146			Treatment in combination with aspirin following cardiac stent insertion	Compliance with Authority Required procedures - Streamlined Authority Code 3146
--	-------	--	--	---	---

	C3879			Treatment of acute coronary syndrome (myocardial infarction or unstable angina) in combination with aspirin	Compliance with Authority Required procedures – Streamlined Authority Code 3879
--	-------	--	--	---	---

(b) insert in numerical order following existing text:

	C4165			Cardiac stent insertion The treatment must be in combination with aspirin; The treatment must follow insertion of a cardiac stent	Compliance with Authority Required procedures - Streamlined Authority Code 4165
	C4166			Acute coronary syndrome (myocardial infarction or unstable angina) The treatment must be in combination with aspirin	Compliance with Authority Required procedures - Streamlined Authority Code 4166

¹Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the *Legislative Instruments Act 2003*.

See <http://www.frli.gov.au>.